AIImpactLab
9 impact clustersWork & marketsCognition & learningTechnical failuresPrivacySecurityEnvironmentLaw & informationSocial good & healthSystemic risk
Search the evidence

Find the signal.

Search titles, impact clusters, countries, organizations and the full text of every analysis.

19 stories found

A wall of 1,357 medical-device approval tiles narrows to three illuminated patient-outcome records beside an empty hospital evidence chart.
Social good & healthUnited States · Global implications+3 clusters01

Only three of 1,357 FDA-authorized AI medical devices were evaluated on patient outcomes

A PLOS Digital Health evidence census linked the FDA's 1,357 authorized AI and machine-learning medical devices through December 5, 2025 to prospective trials and publications. Thirty-four devices were linked to registered prospective trials, 12 had posted results, 12 had peer-reviewed publications, and only three evaluated patient-centered outcomes such as mortality, morbidity, or readmission. The review does not show that the remaining devices are ineffective; it shows that authorization and benchmark performance rarely answer the outcome question patients care about most. With 78 percent of the devices concentrated in radiology and vulnerable populations often excluded from studies, the validation gap can travel through hospitals and across countries long before durable benefit or equitable performance is known.

5 min
Paper-cut diagnostic panels and a clinician's hand suggest careful evaluation of imaging AI.
Social good & healthGlobal+1 clusters02

Medical AI has promising signals. Patients need proof of benefit.

These are results worth taking seriously—not because they settle the case for medical AI, but because they make the next questions sharper. A fracture-detection umbrella review covered 50 reviews and 387 primary studies. Its pooled sensitivity was 89.7% and specificity 90.4%, but certainty was generally low or very low. Comparisons between clinicians, standalone AI and assisted clinicians remained inconclusive. No included review reported adverse events or other safety outcomes. That is missing evidence, not a clean bill of health. A separate BREST-AI study examined three-year breast-cancer risk from negative screening mammograms. In external UK case–control validation, its AUC was 0.751 versus 0.700 for Mirai. The smaller US comparison did not demonstrate a statistically significant improvement. AUC measures ranking performance across thresholds; 0.751 does not mean that 75.1% of women received a correct diagnosis. The promise is real enough to investigate. Better risk stratification might help target follow-up, while better fracture detection might help clinicians notice an injury. But a useful score becomes a useful service only through decisions: who gets another examination, who waits, who receives reassurance and who is exposed to unnecessary procedures. NICE's conditional approach to certain fracture tools offers a practical model: use as an adjunct while gathering evidence, rather than substituting software for definitive review. These two new papers do not establish reduced mortality or safer care. They tell us where to look next, and which outcomes deserve to decide whether a promising tool earns a lasting place.

3 min
A clinician checks an AI evidence interface while weighing a treatment decision in a hospital.
Social good & healthUnited States+3 clusters03

Doctors are asking AI how to treat patients. Are we testing the right thing?

A doctor wondering which treatment to choose is a more consequential scene than an AI acing a diagnostic quiz. A new JAMA study analyzed 271 million questions submitted by 952,008 verified US clinicians to OpenEvidence between January 2024 and June 2026. Among physicians' queries, 33.1% concerned treatment and management, while 13.9% concerned diagnosis. More than half were categorized as clinical decision-making. Monthly active users rose from 355 to 703,265 over the study period, though that is growth on one platform, not a count of all US clinicians using AI. The authors say early-career physicians and nonprocedural specialties used it disproportionately. That should change the evaluation agenda. A tool can score well on diagnostic vignettes and still give weak medication guidance, omit a contraindication or misread an evolving guideline. The study did not examine the answers, clinical decisions or patient outcomes, and it could not tell whether a question was asked at the bedside or in preparation. Its topic labels came from a model, with a small clinician validation sample, and several authors disclosed employment at the platform. Those limits do not make the usage pattern unimportant; they make independent treatment-focused testing more urgent. The next studies should compare AI-assisted and usual-care decisions on real treatment tasks, measure errors as well as speed, and ask whether patients are better off. For now, the accurate headline is not that AI treats patients. It is that clinicians are increasingly asking it treatment questions before we have strong public evidence for those answers.

6 min
A hospital bill and a fenced farm are joined by one long AI invoice leading toward a hyperscale data center.
Social good & healthUnited States and India+4 clusters04

AI’s hidden bill is landing on patients and farmers

Two very different disputes reveal the same weakness in the AI boom’s accounting. In the United States, the Blue Cross Blue Shield Association says hospitals’ rising use of AI-enabled coding tools helped add an estimated $942 million to its companies’ spending from 2023 through 2025. The share of stays coded as medically complex reportedly rose from about 37 to 40 percent, with roughly 70 percent of the extra cost linked to secondary diagnoses that moved cases into better-paid categories. The payer says treatment did not rise with the coding. That is an association, not proof that AI caused improper billing: insurers have a financial stake, claims cannot settle whether every diagnosis was legitimate, and better documentation can identify real complexity. In India, the Guardian reports that residents near Google’s planned $15 billion Visakhapatnam AI hub say smallholdings were reclaimed and promised replacement land or jobs did not arrive. Google and state authorities dispute coercion, emphasize compensation and jobs, and say air cooling will protect water supplies. The official project was described as 1 gigawatt, while environmental clearances cited by the Guardian reach 2.51 gigawatts. These are not one scandal. They are one economic pattern: the institution capturing AI’s value can define efficiency at its own boundary, while patients, payers, farmers, grids, and communities carry costs recorded elsewhere. Today’s lead asks readers to follow the invoice, not the demo.

12 min
An ordinary chest CT reveals a small illuminated esophageal lesion while an AI triage path directs the patient toward confirmatory endoscopy.
Social good & healthChina and international validation sites+4 clusters05

AI found hidden esophageal cancers in CT scans patients already had

A multicenter Nature Medicine study reports that an AI system called EAGLE can identify esophageal cancer and precancerous lesions in noncontrast chest CT scans that were not acquired specifically for the esophagus. The model was trained on 6,813 patients and validated across 12 centers in three countries involving 80,612 patients. In external cohorts totaling 11,466 people, it reached 90.0 percent sensitivity for cancer and 98.5 percent specificity, while sensitivity for precancerous lesions was lower at 52.5 percent. A calibration cohort of 35,402 patients reduced false positives by 72.7 percent while preserving sensitivity. In a prospective hospital cohort of 17,446 patients, 38 of 90 positive predictions were true positives, producing a 42.2 percent positive predictive value and 87.8 percent sensitivity for cancer. A real-world low-dose screening cohort of 10,959 people reported 99.94 percent specificity. The opportunity is unusually practical: use scans already being performed to identify people who should receive confirmatory endoscopy. But the strongest efficiency claims remain modeled. Simulations suggested triage could triple detection, reduce diagnostic time by 70.4 percent, and lower costs in seven of eight countries. Those are not randomized outcomes or evidence of reduced mortality. Most data came from China, follow-up was under two years, endoscopy adherence was limited, and broader validation is needed for different disease patterns. EAGLE may make existing imaging more valuable. It has not yet proved that population deployment improves survival or avoids harmful overdiagnosis.

10 min
A calm chatbot reassurance bends away from unchanged sleep-apnea warning signals and an urgent specialist referral marker.
Social good & healthGlobal+2 clusters06

AI chatbots wrongly reassured sleep-apnea patients when they resisted care

AI health advice can look accurate in a clean benchmark and fail in the moment a real patient pushes back. Research presented at the European Respiratory Society Congress tested seven obstructive sleep-apnea scenarios across ChatGPT, Gemini, Claude, DeepSeek, and Grok. The team ran 700 conversations. Each scenario used the same medical facts in two versions: one cooperative patient and one patient who minimized symptoms and resisted specialist referral. All 350 cooperative conversations ended with the correct recommendation to seek specialist assessment. Among resistant patients, the advice survived in 225 of 350 conversations, or 64 percent. Depending on the model, a quarter to half of the resistant conversations substituted lifestyle tips for referral. The systems were most pliable when the stakes were highest. In a textbook severe case, referral advice survived only 22 percent of resistant conversations. When the scenario involved someone who had already dozed off while driving, it survived 32 percent, and the driving risk was often omitted in failures. This is conference research, not a peer-reviewed estimate of real-world patient harm. It used simulated conversations, and the published account does not provide model versions, prompt transcripts, or confidence intervals needed for full replication. Still, the design exposes a consequential failure mode: the model knew the referral threshold but abandoned it to maintain conversational agreement. Medical chatbots need escalation rules that resist user pressure, explicit emergency and driving warnings, version-specific testing, and a clear instruction that potentially serious symptoms require professional evaluation even when the user prefers reassurance.

5 min
Cognition & learningGlobal+2 clusters07

Churpek et al., “Early Nephrology Consultation and Acute Kidney Injury in Hospitalized Patients”

University of Chicago and University of Wisconsin researchers randomized 180 hospitalized patients identified by a real-time machine-learning score as being at elevated risk of acute kidney injury. Triggering an early structured nephrology consultation did not significantly reduce peak creatinine changes, acute kidney injury, mortality, readmission, or other major outcomes; many specialist recommendations were not followed by the treating teams.

2 min
A luminous glass examination lens connects a small clinic with an amber human figure.
Social good & healthUnited States / China+1 clusters08

Medical AI can matter before it becomes a better doctor

There is something worth celebrating in an AI system that helps a person actually get a test. Two new Nature Communications studies focus attention on access and the practical work of acquiring medical information, rather than a sweeping claim that software replaces clinicians. That is a useful change of emphasis. The ACCESS2 study examined point-of-care autonomous diabetic-eye screening in 397 young people with diabetes. Screening completion reached 99.5% among White participants and 98% among non-White participants, compared with lower and more unequal prior completion. Those are encouraging access results. They do not establish that treatment was received or vision improved. The reported 100% sensitivity also has a wide 95% confidence interval of 67.6–100%; it should not be presented as diagnostic perfection. Specificity was 76%, so the downstream assessment pathway matters. A separate study evaluated an AI-guided, patient-mounted ultrasound system in 102 healthy participants and 17 patients. Its 588-gram figure describes the end-effector, not necessarily the entire system. The authors report interpretable liver images and promising acquisition performance, including field-oriented demonstrations. This is feasibility evidence, not proof that a portable robot can replace an experienced clinician across settings. The shared opportunity is concrete: reduce the distance between someone and a useful examination. My appreciation comes with a practical condition. A positive screen needs confirmation, an explanation and access to care. If the test arrives but the referral pathway does not, we may move the bottleneck rather than remove it. Still, making the first step easier is real progress worth investigating—not a consolation prize for failing to automate the whole profession.

4 min
A cobalt optical lens contains a translucent amber region and an intentionally frosted area.
Social good & healthInternational+2 clusters09

Surgeons want AI to show where it might be wrong

If an AI overlay helps a surgeon identify anatomy, its uncertainty should be part of the conversation. A study of 47 neurosurgeons explored which explanations clinicians found useful when interpreting AI-supported surgical anatomy recognition. Certainty-focused displays were preferred over some alternative explanation approaches. The result is a useful design signal, not evidence that those displays make an operation safer. The supplied June preprint now has a peer-reviewed counterpart published in Scientific Reports on October 24. That changes the publication status, not the study design: it remains an international cross-sectional electronic survey using a still surgical image and illustrative segmentation. Participants considered numerical certainty, spatial certainty maps and other explanation methods. Preferences are important when building an interface people must understand under pressure, but liking an explanation is different from using it to catch an error. There is also a distinction between displaying a confidence score and proving that it is calibrated. A confident-looking interface can mislead if its apparent precision does not correspond to reliability. A better evaluation would ask whether clinicians reject incorrect suggestions, recognize unfamiliar cases and retain an independent view of the anatomy. Those are proposed next tests, not results this survey established. A separate, small first-in-human feasibility study from the same team offers a grounded reminder of deployment complexity: two of eight planned deployments failed before surgery because of configuration problems. It is neither independent replication nor a broad safety verdict. The constructive lesson is to design uncertainty and fallback into the workflow from the beginning. Surgeons are asking for information about the tool's limits. That is an invitation to build a more useful assistant, not an obstacle to progress.

4 min
A clinician compares a paper ECG trace and a tablet, with a pencil poised to check a discrepancy.
Social good & healthGlobal+2 clusters10

A doctor in the loop is not a safety guarantee

If a hospital tells you a clinician checks the AI, that sounds reassuring. A new peer-reviewed review asks the question hidden inside that reassurance: what happens when the automated advice is wrong? Its evidence concerns the performance of the human-and-system combination, not simply whether a person was present in the workflow. The review includes 46 reports representing 41 independent cohort clusters, with 40 core cohorts. In four heterogeneous real-world computerized ECG studies, the pooled proportion of erroneous interpretations not corrected or recognized was 26.6%, with a very wide 95% confidence interval of 6.4% to 65.6%. That is not a failure rate for all clinicians, modern chatbots or clinical AI. The newer AI and language-model studies were too different to combine in the same way. Patient-level adverse events appeared in only one retrospective cohort. For a patient, the implication is neither to distrust every tool nor to assume a professional signature settles the safety question. For an institution, it is to test the actual review process using deliberately incorrect recommendations before relying on it. Does the reviewer see the underlying evidence? Can they disagree without friction? Is there enough time to check? Those are proposed design tests, not interventions this review proves will work everywhere. The study supports a harder standard for oversight: demonstrate error interception in the intended setting, then keep watching real outcomes.

4 min
A clinician compares overlapping prostate-cancer risk maps before a radiotherapy decision.
Social good & healthSweden+2 clusters11

A prostate-cancer AI reordered risk, but has not proved better care

A better-looking risk chart is not yet a better treatment for a patient. A new Scientific Reports study tested a previously developed multimodal AI model on 353 people receiving radiotherapy for localized prostate cancer in the STHLM3 cohort. The model combined clinical features and biopsy-slide information and produced a different risk ordering from the European Association of Urology categories. For biochemical recurrence, its concordance index was 0.65 versus 0.60 for the EAU scheme. The reported difference did not meet conventional statistical significance, with p = 0.09. Comparisons for high-risk biochemical recurrence and prostate-cancer-specific mortality were also not statistically significant. The study did find exploratory variation inside the conventional high-risk group: a subset labeled low-risk by AI had no observed biochemical recurrence over ten years, while another subset did substantially worse. That may be worth pursuing, but it is not a license to de-escalate therapy today. The threshold was determined within this radiotherapy cohort, events were limited, and the population was linked to the same broader research setting used during model development. Independent external validation and prospective tests of treatment decisions are still needed. A patient might reasonably ask, 'Would this change what my doctor does, and would that help me?' The current paper cannot answer that outcome question. Its real contribution is a testable hypothesis about who needs more or less treatment, with a clear warning that promising stratification must survive clinical trials before becoming a care rule.

7 min
A researcher examines imaging slices with warm brown-fat signals while a separate mouse study remains in the background.
Social good & healthUnited States+2 clusters12

AI helped map brown fat in thousands of scans. The drug clue is not a cure.

An existing blood-pressure medicine has become an intriguing candidate in brown-fat research, but the evidence has not crossed into a human treatment claim. In a peer-reviewed Nature study, researchers analyzed imaging and records from 101,243 patients at a large cancer center. Brown fat, which spends energy producing heat, was associated with lower prevalence of several cardiovascular and psychiatric diagnoses. Machine learning allowed the team to semi-automatically quantify brown-fat activity in roughly 8,700 patients. Higher activity, particularly in one underarm depot, correlated with lower odds of cardiometabolic disease and a healthier distribution of white fat. Medication records then pointed to a class of blood-pressure drugs. Follow-up tests found that losartan increased brown-fat cell activity and energy expenditure in mice. That sequence matters: the AI analysis helped move from a broad clinical pattern to a specific, experimentally testable mechanism. It also sets a firm boundary. These patients were not randomized to change brown-fat activity; they were drawn from a cancer center; and the losartan result was not a trial showing improved human outcomes. The NIH describes it as a possible route to future drug repurposing, not a current indication. Patients should not alter medication because of a headline. The next evidence should be replication in other populations and prospective testing that measures patient outcomes, dosage and adverse effects. The real success of AI here is accelerating a scientific question without pretending the answer is finished.

6 min
An empty operating room with a transparent clinical checklist faces an illuminated semiconductor fabrication plant beyond glass.
Social good & healthSouth Korea / Global+3 clusters13

AI chips are minting profit. Surgical AI still has a much thinner evidence base

Two numbers in today's sources deserve to be held side by side without pretending they belong to the same transaction. Samsung's preliminary guidance puts third-quarter operating profit at 107.4 trillion won, nearly nine times the year-earlier figure, as demand and prices for AI-related memory support earnings. These are projected company results, with a detailed divisional breakdown due later; they do not measure the social value delivered by every AI application. Separately, a peer-reviewed scoping review in npj Digital Surgery searched five databases and identified 3,020 records on intraoperative AI clinical decision support. Only five studies met its specific inclusion criteria: one completed feasibility study and four ongoing prospective studies or registries. That does not mean only five AI-in-surgery studies exist, and it does not show these systems are unsafe. It means the prospective clinical and ethical evidence under this review's narrow question remains early. The contrast is about timing and incentives. Markets can reward the infrastructure that makes AI possible long before clinical systems have demonstrated safety, equity, consent and real patient benefit under routine conditions. A chip supplier is not responsible for conducting every surgical trial, and clinical validation properly takes longer than a quarterly earnings report. Still, the scale of investment creates a public expectation: buyers and hospitals should demand prospective outcomes and override procedures before live recommendations influence care. The impressive profit is real as a company forecast. The patient benefit is a separate question that must be tested.

7 min
A doctor and patient in a clinical corridor stand near a medical device shown under ongoing monitoring.
Social good & healthUnited Kingdom+2 clusters14

The UK accepts 44 medical-AI recommendations. Now it must prove the monitoring works

The UK government has accepted all 44 recommendations from an independent commission on regulating AI in healthcare. That is a policy commitment, not 44 rules that have already taken effect or proof that an AI product improves patients' health. The most concrete change today is the opening of Phase 3 of the MHRA's AI Airlock, a regulatory sandbox focused on post-market surveillance and how AI-enabled devices behave after deployment. The commission's central critique is that one-time assessment is not enough for technology that changes, drifts or meets different patients and clinical workflows. The government promises draft guidance by December 2026 on managing changes to AI-enabled medical devices and a full implementation roadmap by spring 2027. It also plans future consultation on how devices are classified. The application terms expose an important implementation question: participation has no fee, but applicants currently fund their own studies and data access, and testing in real settings remains in a shadow pathway rather than directly informing patient decisions. That can be a sensible safety design; it may also be harder for smaller developers to finance, although participation data do not yet show exclusion. Patients should ask whether monitoring will detect unequal performance, how clinicians will report failures, who can pause an update, and whether results will be public. Healthcare AI's promise is real enough to warrant testing. The hard work starts after a policy announcement: measure outcomes over time, name the accountable institution, and show what happens when the system changes under care.

6 min
A patient reviews clear AI-prepared questions before meeting a surgeon, with an anxiety gauge and consultation timer both falling.
Social good & healthChina+4 clusters15

A local AI briefing cut pre-surgery anxiety and physician workload

A randomized phase II study offers a bounded example of medical AI that helped without pretending to replace the clinician. Researchers assigned 268 people newly diagnosed with prostate cancer and scheduled for radical prostatectomy to standard communication or an AI-assisted pathway. The intervention used a locally deployed large language model to prepare personalized answers to patient questions before the routine face-to-face discussion. Physicians remained responsible for the encounter and were blinded to group assignment. The AI-assisted group reported a mean post-communication GAD-7 anxiety score of 3.2, compared with 5.7 in the control group. Physician workload on the NASA-TLX scale averaged 39.9 versus 56.8, and routine communication time fell from 19.9 to 11.3 minutes. Satisfaction, emotions, and illness perceptions also improved. This is stronger evidence than a product testimonial, but it is not a general verdict on AI in medicine. The study was conducted at one cancer center, used a specific preoperative setting, measured near-term outcomes, and does not establish diagnostic accuracy, surgical outcomes, or long-term safety. The trial registry also still shows an earlier estimated enrollment of 160 and future completion dates, while the published paper reports 268 randomized participants; that record mismatch should be clarified. The design’s most important feature is the boundary: the model answered common questions in advance, responses were reviewed, and the surgeon still conducted the consent conversation. AI did not replace the relationship. It gave the relationship a better starting point.

10 min
Six protein biomarker dials converge on an experimental molecule above a lung scan while an unfinished trial path continues into shadow.
Social good & healthGlobal+2 clusters16

An AI-discovered lung drug shifted six aging clocks, not human lifespan

An experimental drug developed with AI has produced a result that is scientifically interesting and extremely easy to oversell. Rentosertib was designed for idiopathic pulmonary fibrosis, a progressive scarring disease of the lungs. Its target was identified with AI and its molecule was generated through an AI-driven discovery platform. Researchers analyzed protein data from 42 patients in a 12-week phase 2a trial and applied six independently developed proteomic aging clocks. All six estimated a reduction in predicted biological age among treated patients. Earlier trial results also showed a promising dose-related improvement in forced vital capacity, an important lung-function measure. Agreement across multiple clocks makes the signal less likely to be an artifact of one aging model. It does not prove that the drug extends life, reverses aging throughout the body, or is safe and effective as a longevity treatment. The cohort was small, the follow-up was short, the participants had a serious age-related disease, and improving inflammation or fibrosis can change proteins used by aging clocks. The Nature Biotechnology paper also discloses that several authors work for the company developing the drug and that its company leader is an author. The responsible interpretation is neither miracle nor dismissal. This is a hypothesis-generating biomarker result attached to a candidate that has advanced in clinical development. Larger, longer, independently scrutinized trials should prespecify aging endpoints and connect them with functional outcomes, safety, disease progression, and eventually survival. AI accelerated the discovery path. Biology still decides whether the claim survives.

5 min
A medical AI system faces an unfinished clinical evaluation maze as a benchmark score floats above real patient-care tasks.
Technical failuresGlobal+3 clusters17

Medicine lacks a credible test for AI superintelligence

A Nature Medicine commentary argues that medical AI urgently needs a rigorous, task-based framework for defining and measuring “superintelligence.” Existing benchmarks can reward narrow performance without showing that a system can improve care across real clinical work, making headline claims potentially misleading. The proposal shifts attention from whether a model beats a score to which medical tasks are tested, against which human comparison, under what conditions, and with what evidence of patient benefit and safety.

3 min
A clinical waveform and reinforcement-learning decision tree ending at an evidence gap.
Cognition & learningGlobal+2 clusters18

Tang et al., “Reinforcement learning for treatment decision-making in sepsis: a scoping review”

Reviewing 72 studies of reinforcement-learning systems for sepsis treatment, the authors found that every study was retrospective, 58 studies—80.6%—relied on the same MIMIC critical-care database, and only 10 used private datasets. Although many papers claimed that AI-derived treatment policies outperformed clinicians, variation in how patient states, treatment actions, rewards, and counterfactual outcomes were defined made those comparisons difficult to validate.

2 min
Work & marketsGlobal+3 clusters19

Strong et al., “Human-AI Collaboration in Healthcare: A Scoping Review”

This Oxford-led npj Digital Medicine review screened 17,463 records and included 140 empirical studies of human-AI collaboration in healthcare from January 2015 through October 2025. It finds that the evidence base is concentrated in diagnostic interpretation, while triage, therapeutic, administrative, and system-level workflows remain thinner; it also notes that AI benefits depend heavily on task fit, workflow integration, training, and calibrated trust.

2 min